Business
AnaptysBio is a clinical-stage biotechnology company focused on immunology therapeutics, with royalty and milestone revenue from out-licensed antibodies including Jemperli and imsidolimab.
AnaptysBio revenue rose 157.0% to $234.6M, free cash flow turned positive, and the net loss narrowed to $13.2M.
The read at a glance✓ Audited against SEC data
- Business mix — Immunology pipeline and royaltiesNote
- Revenue — Revenue rose 157.0% to $234.6MOK
- Profitability — Net loss narrowed 90.9%OK
- Cash — Free cash flow turned positiveOK
- Balance sheet — Equity fell 47.5%Watch
- Insiders — 0 buys / 26 sellsWatch
- Accounting — Altman-Z distress; EQ unavailableWatch
Where the revenue comes from
Fiscal 2025, as ANAPTYSBIO, INC reports it. History and quarterly detail are in the app.
- Anaptys Bio Generated Anti PD1Jemperli Dostarlimab$258.0M
- License$9.5M
- Transaction Service$200K
Leadership changes
From ANAPTYSBIO, INC's own filings, the day they're filed.
- Christopher M. Murphy · Chief Financial Officer · appointmenteff. 2026-05-11
- Owen Hughes · director · appointmenteff. 2026-05-11
- J. Anthony Ware · directors · departureeff. 2026-04-20
Latest filings
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-30
- DEF 14A · Annual proxy (pay & governance)2026-06-29
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ANAPTYSBIO, INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.